SLC5A2 and cardiovascular disorder: The current guideline recommends, after individual consideration, the initial combination of metformin with SGLT2 inhibitors or GLP-1 receptor agonists as the first-line therapy in patients with cardiovascular disease or clinically relevant renal disease [25].